We're thrilled to announce that Curenetics has been selected to be part of the prestigious KQ Labs cohort 7!

We are thrilled to announce that Curenetics will feature in a 4-part Christmas Special of “The Immunobuddies” podcast, launching this Friday, 20th December!
This exclusive series takes a deep dive into how AI is transforming oncology and responses to immunotherapy

We at Curenetics are delighted to be chosen as one of the 10 new start-ups welcomed into the growing community of the Paris Saclay Cancer Cluster (PSCC). We believe in the power of technology to transform cancer care, and it’s exciting to see the PSCC community providing a world-class ecosystem to accelerate these breakthroughs.

Our founder Sola Adeleke and team presented our latest immunotherapy response prediction project at St. George's University Hospital, hosted for 28 medical professors from Hebei Medical University* from China.

🎙 In the latest episode E137 of ‘AI for Pharma Growth’ we dive deep into the transformative role of AI in cancer treatment with Sola Adeleke, the founder and CEO of Curenetics.

Curenetics, alongside other world-leading medtech and AI companies, is thrilled to establish its global headquarters in London, positioning itself ideally to forge the strategic partnerships and connections essential for future growth.

Watch Curenetics pitch live at the Innovation Challenge Finals at our upcoming MSDUK & ESDP Business Diversity Connect!

Over 3 million patients are living with cancer in the UK alone, with 1,000 new diagnoses every day.
Curenetics is working to predict cancer treatment responses using powerful AI technology accurately ✨

In the new Nexus Meets series, our members joined Nexus to give insights on Curenetics and what we are working with.

Curenetics is a London-based company that’s working on a way to predict patient responses to treatment. Their AI tool uses patient imaging profiles, tissue examinations, clinical information and DNA to help doctors make better decisions about treatment options for patients.

Today we introduce you to Sola Adeleke (Curenetics) & more speakers who promise to make #PING2024 a must attend event.

Curenetics as a part of a Life Sciences themed trade mission with the Grow London Global programme - supported by the Mayor of London and UKSPF

Curenetics, Queen Mary University London (QMUL), Oracle Cancer Trust and South East Health Technologies Alliance (SEHTA) are working collaboratively to pioneer a transformative approach to oral cancer detection through the Novel AI-Enabled qMIDS Test. The research is funded by the National Institute for Health and Care Research (NIHR), the research partner of the NHS, public health and social care.

Following MedCity’s Collaborate to Innovate Speed networking event held on 25 April 2022, Curenetics – an innovative AI Diagnostics company – and Prof Yong-Jie Lu – a leading expert in molecular oncology – and his team at Queen Mary University of London (QMUL) signed a Confidential Disclosure Agreement (CDA).

If starting his own business wasn’t achievement enough, Sola Adeleke's business Curenetics has the potential to improve cancer patient's prognosis, and their quality of life AND save the NHS millions

Sola Adeleke, the founder of Curenetics reflects on the top three things he wishes he’d known prior to starting his business Curenetics in 2018.

Our CEO Sola Adeleke recently attended Cardiff University for the Learn2Innovate Student Healthcare Innovation Programme as the Cross University Collaborative innovation task group Mentor.

Our Founder and CEO, Dr. Sola Adeleke, at the House of Parliament Roundtable sharing his thoughts on the success of UK Biobank. Sola expresses the need for further access to data for innovative spinouts.

As the part of the innovative digital Healthcare organisation, we were delighted to attend this great event organised by the Health Foundry discussing various ideas and innovations with this diverse talents in MedTech.

Description goes An innovative healthcare start-up is re-evaluating how patients, recruiters and other healthcare organisations access clinical trials. Over 9 weeks, Brunel University London Design students designed a variety of concepts for Curenetics new clinical trials app

Earlier this week we were delighted to announce the launch of nine match-funded research projects made possible through MedCity’s Collaborate to Innovate: London Diagnostics programme. Now at the beginning of their 12-month journey, each project team will work to develop diagnostics tools and technologies capable of transforming outcomes for diseases adversely impacting diverse patient populations. Here we introduce each project, the partners involved, and their objectives.

Nine London-based diagnostic healthcare SMEs developing screening tests and technologies to detect some of the UK’s most debilitating diseases, have been awarded match-funded research partnerships with experts in academia and industry.